Hormone Replacement Therapy Market to Reach USD 21.49 Billion by 2028; AbbVie and Neurocrine Biosciences, Inc. Gains Sanction from the U.S. FDA for ORIAHNN to Make Noticeable Progress

The global hormone replacement therapy market size was USD 13.40 billion in 2020. The market is projected to grow from USD 14.17 billion in 2021 to USD 21.49 billion in 2028 at a CAGR of 6.1% in the 2021-2028 period. This information is provided by Fortune Business Insights, in its report titled, “Hormone Replacement Therapy Market Size, Share & COVID-19 Impact Analysis, By Therapy Type (Estrogen and Combinations Replacement Therapy, Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, and Testosterone Hormone Replacement Therapy), By Indication (Menopause, Hypothyroidism, Male Hypogonadism, and Growth Hormone Deficiency), By Route of Administration (Oral, Transdermal, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retails Pharmacies & Stores, and Online Pharmacies), and Regional Forecast, 2021-2028.”

COVID-19 Impacts:

Lack of Hormone Replacement Therapy amid COVID-19 to Hinder Global Market

The impact of COVID-19 on the hormone replacement market has been opposing, owing to the wide-ranging insufficiency of therapy supplies throughout the world. The absence has further resulted in the upsetting of pre as well as post-menopausal women across the globe. Owing to the COVID-19 pandemic, the struggle of the producers to attain raw materials resulted in the insufficiency of therapy products.

FDA Sanctions Weekly Therapy for Adult Growth Hormone Absence

In August 2020, the U.S. Food and Drug Administration authorized Sogroya (somapacitan) for grownups with growth hormone shortage. Sogroya is the foremost human growth hormone (hGH) therapy that grownup patients only consume once every week in the form of injections under the skin; other FDA-sanctioned hGH formulations for adults with growth hormone shortage is required to be monitored daily.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/hormone-replacement-therapy-hrt-market-102543

Rise in Prevalence of Various Hormonal Disorders to Drive Hormone Replacement Therapy Market Growth

Menopause is one of the most general gynecological concern in women. However, growth hormone deficiency is also deliberated as a unique endocrine ailment, which contains numerous symptoms such as condensed energy levels, insulin resistance, lipid irregularities, and low physical actions in adults.

Competitive Landscape:

In terms of competitive scenario, the vital players present in the market are Novo Nordisk A/S and Pfizer Inc, owing to their assorted product portfolio across the world. In terms of revenue, Novo Nordisk possesses the dominance, owing to its bestseller product Norditropin. The substantial upscale of the product globally is projected to spur the growth of the market during the forecast period.

List of Key Players Mentioned in the Report:

• Novo Nordisk A/S (Bagsværd, Denmark)


• Pfizer Inc. (New York, U.S.)


• AbbVie’s (Lake Bluff, U.S.)


• Merck KGaA (Dermstadt, Germany)


• Endo International plc (Dublin, Ireland)


• Allergan plc (Irvine, U.S.)


• Eli Lilly and Company (Indianapolis, U.S.)


• Mithra Pharmaceuticals (Liege, Belgium)


• Amgen (Thousand Oaks, U.S.)

Industry Development:

• May 2020: AbbVie and Neurocrine Biosciences, Inc. stated that they gained sanction from the U.S. FDA for ORIAHNN, as a treatment and administration for substantial menstrual bleeding related with uterine fibroids in pre-menopausal women.

Further Findings:

• Based on type, the market is segmented into estrogen and combinations, growth, thyroid, and testosterone hormone replacement therapy. Estrogen and combinations replacement therapy dominated the market, owing to rise in awareness related to menopause symptoms across the globe.


• North America stood at USD 7.07 billion in 2020 and held the maximum market share. Moreover, the market is expected to dominate the global market, owing to rise in prevalence of menopause and growth hormone deficiency disorders.

Table of Segmentation: